Do You Qualify for a Dupixent CTCL Case Review?
Lawyers are reviewing claims for people who used Dupixent and were later diagnosed with cutaneous T cell lymphoma or a related T cell lymphoma. The questions below help determine whether a free review may make sense. Only an attorney can assess your specific situation.
- No fee unless you recover
- 100% confidential
- Nationwide claims
- MDL 3180 · District of New Jersey
General Criteria Many Intake Teams Look For
- You were prescribed and used Dupixent (dupilumab) for an approved condition, such as eczema or atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, or bullous pemphigoid.
- You were later diagnosed with cutaneous T cell lymphoma (CTCL), mycosis fungoides, Sézary syndrome, or another T cell lymphoma.
- Your diagnosis came after you started Dupixent.
Things That May Affect a Claim
- How long you used Dupixent.
- The timing between starting the drug and your diagnosis.
- Whether you had a prior lymphoma or leukemia before starting Dupixent.
- Your state deadline (statute of limitations), which varies and can be short.
Families and Wrongful Death
If a loved one used Dupixent and died after a CTCL diagnosis, a surviving family member may be able to ask about a wrongful death review.
Why Timing Matters
Each state sets its own filing deadline, generally measured in a few years and often starting when the injury or its cause was or should have been discovered. Because deadlines can pass, it is wise to ask sooner rather than later.
Attorney advertising. Eligibility depends on the facts of each case and applicable law. Submitting information does not create an attorney client relationship and does not guarantee representation or any outcome. Prior results do not guarantee a similar outcome.